

**GENOMIC VALLEY BIOTECH LIMITED**  
**Regd. Off: 4 KM STONE BERI CHHARA ROAD, TEHSIL-BAHADURGARH**  
**DISTT-JHAJJAR, HARYANA**  
**CIN: L01122HR1996PLC033029**

Genomic Valley Biotech Limited today reported its financial performance for the Quarter and Nine Months ended  
31 December 2016

Highlights of the Un-Audited Financial Results as compared to the previous year are:

**PART I** (Amount in ₹)

Sr. No.	Particular	Quarter Ended			Nine Month Ended		Year Ended
		31-Dec-16 Unaudited	30-Sep-16 Unaudited	31-Dec-15 Unaudited	31-Dec-16 Unaudited	31-Dec-15 Unaudited	31-Mar-16 Audited
	<b>Part I</b>						
<b>1</b>	<b>Income From Operations</b>						
	a) Net Sales/Income From Operations (Net of excise duty)	786,000.00	960,450.00	268,000.00	3,196,344.00	824,540.00	1,090,205.00
	b) Other Operating Income	-	-	-	-	-	-
	<b>Tota income from operation (net)</b>	<b>786,000.00</b>	<b>960,450.00</b>	<b>268,000.00</b>	<b>3,196,344.00</b>	<b>824,540.00</b>	<b>1,090,205.00</b>
<b>2</b>	<b>Expenses</b>	-	-	-	-	-	-
(a)	Cost of materials consumed	266,381.00	440,075.00	183,795.00	948,972.00	662,985.00	729,289.00
(b)	Purchases of Stock-in-Trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-	-
(d)	Employee benefits expense	685,801.00	730,521.00	318,112.00	1,670,419.00	1,104,612.00	1,337,816.00
(e)	Depreciation and amortization expense	122,317.86	122,317.86	124,213.67	363,747.32	372,641.01	501,954.68
(f)	Other expenses (Any item exceeding 10% of the total expenses relating to continuing operation to be shown seprately)	235,665.90	391,824.68	1,438,065.00	1,014,555.78	3,312,937.72	3,619,174.72
	<b>Total Expenses</b>	<b>1,310,165.76</b>	<b>1,684,738.54</b>	<b>2,064,185.67</b>	<b>3,997,694.10</b>	<b>5,453,175.73</b>	<b>6,188,234.40</b>
<b>3</b>	<b>Profit / (Loss) from operations before other income, finance costs and exceptional item</b>	<b>-524,165.76</b>	<b>-724,288.54</b>	<b>-1,796,185.67</b>	<b>-801,350.10</b>	<b>-4,628,635.73</b>	<b>-5,098,029.40</b>
4	Other Income	154,750.00	104,750.00	1,827,063.18	-123,421.83	2,890,284.06	1,649,603.73
<b>5</b>	<b>Profit/loss from ordinary activity before financial cost &amp; exceptional items(3±4)</b>	<b>-369,415.76</b>	<b>-619,538.54</b>	<b>30,877.51</b>	<b>-924,771.93</b>	<b>-1,738,351.67</b>	<b>-3,448,425.67</b>
6	Financial cost	-	-	-	-	-	-
<b>7</b>	<b>Profit from ordinary activity after financial cost but before exception item</b>	<b>-369,415.76</b>	<b>-619,538.54</b>	<b>30,877.51</b>	<b>-924,771.93</b>	<b>-1,738,351.67</b>	<b>-3,448,425.67</b>
8	Exceptional Item	-	-	-	-	-	-
<b>9</b>	<b>Profit From ordinary activities before tax</b>	<b>-369,415.76</b>	<b>-619,538.54</b>	<b>30,877.51</b>	<b>-924,771.93</b>	<b>-1,738,351.67</b>	<b>-3,448,425.67</b>
10	Tax expenses	-	-	-	-	-	-100,600.00
<b>11</b>	<b>Net Profit/(Loss) from ordinary activities after tax</b>	<b>-369,415.76</b>	<b>-619,538.54</b>	<b>30,877.51</b>	<b>-924,771.93</b>	<b>-1,738,351.67</b>	<b>-3,347,825.67</b>
12	Extraordinary item	-	-	-	-	-	-

*Paul Agrawal*  


13	Net profit/(Loss) for the period	-369,415.76	-619,538.54	30,877.51	-924,771.93	-1,738,351.67	-3,347,825.67
14	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500.00	3,054,500.00	3,054,500.00	3,054,500.00	3,054,500.00	3,054,500.00
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	15,085,115.86	15,085,115.86	18,432,941.53	15,085,115.86	18,432,941.53	15,085,115.86
	Earning Per Share	-	-	-	-	-	-
	(a) Basic	-0.12	-0.20	0.01	-0.30	-0.57	-1.10
	(b) Diluted	-0.12	-0.20	0.01	-0.30	-0.57	-1.10

**PART II**

Sr. No.	Particular	Quarter Ended			Nine Month Ended		Year Ended
		31-Dec-16	30-Sep-16	31-Dec-15	31-Dec-16	31-Dec-15	31-Mar-16
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A</b>	<b>PARTICULAR OF SHAREHOLDING</b>						
1	<b>Public Shareholdin</b>						
	Number of Shares	1,092,800.00	1,092,800.00	1,092,800.00	1,092,800.00	1,092,800.00	1,092,800.00
	Percentage of Shareholding	35.78%	35.78%	35.78%	35.78%	35.78%	35.78%
2	<b>Promoters and Promoters Group Shareholding</b>						
	<b>a) Pledge/Encumbered</b>						
	Number of Shares	0	0	0	0	0	0
	Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	0	0	0	0	0	0
	Percentage of Shares (as a % of the total share capital of the Company)	0	0	0	0	0	0
	<b>b) Non - encumbered</b>						
	Number of Shares	1,961,700.00	1,961,700.00	1,961,700.00	1,961,700.00	1,961,700.00	1,961,700.00
	Percentage of Shares (as a % of the total Shareholding of the promoter and promoter Group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	Percentage of Shares (as a % of the total Share Capital of the Company)	64.22%	64.22%	64.22%	64.22%	64.22%	64.22%

<b>B</b>	<b>INVESTOR COMPLAINT</b>	
	<b>PARTICULAR</b>	3 Month ended 31-Dec-16
	Pending at the beginning of the quarter	0
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	0


*Paul Agrawal*



**Notes :**

- 1 The above financial results were reviewed by the Audit Committee and were thereafter approved by Board of Directors of the Company at their respective meeting held on 11th February, 2017.
- 2 Tax expenses includes provision for current tax and deffered tax.
- 3 Previous period's Figures have been re-grouped and / re-arranged wherever considered necessary as per the revised format of the SEBI and amended Schedule III to the Companies Act, 2013 and to make their classification comparable with the current period.

**For and on behalf of the Board of Genomic Valley Biotech Limited**

  
Pankaj Agrawal  
(Director)  
DIN-01165188

Place : Delhi  
Dated : 11.02.2017

Add: G-74, Pushkar Enclave,  
Paschim Vihar, New Delhi-110063